Barclays Maintains Equal-Weight on Prelude Therapeutics, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Peter Lawson has maintained an Equal-Weight rating on Prelude Therapeutics (NASDAQ:PRLD) but lowered the price target from $7 to $5.
August 04, 2023 | 3:07 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays has maintained an Equal-Weight rating on Prelude Therapeutics but lowered the price target from $7 to $5.
The lowering of the price target by Barclays indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100